Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 5/20 | 0.58 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.45 |
| ▸ | CCR1 | P32246 | 1/20 | 0.45 |
| ▸ | PKLR | P30613 | 1/20 | 0.44 |
| ▸ | TACR1 | P25103 | 2/20 | 0.43 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | TET3 | O43151 | 1/20 | 0.42 |
| ▸ | FBXL19 | Q6PCT2 | 1/20 | 0.42 |
| ▸ | CXXC5 | Q7LFL8 | 1/20 | 0.42 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.42 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.42 |
| ▸ | CXXC4 | Q9H2H0 | 1/20 | 0.42 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.42 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3589814 | 0.85 | HSD11B1 (0.45) | HSD11B1PKLRTACR1KMT2AMEN1 | |
| SCHEMBL3585852 | 0.85 | HSD11B1 (0.45) | HSD11B1OPRM1CCR1PKLRTACR1 | |
| SCHEMBL2425390 | 0.85 | HSD11B1 (0.49) | HSD11B1OPRM1 | |
| SCHEMBL23002585 | 0.85 | MAOA (0.61) | HSD11B1OPRM1KMT2ATET3FBXL19 | |
| SCHEMBL3588034 | 0.84 | TACR1 (0.45) | HSD11B1OPRM1TACR1KMT2AKCNA3 | |
| SCHEMBL3599347 | 0.84 | HSD11B1 (0.44) | HSD11B1OPRM1PKLRTACR1 | |
| SCHEMBL3441634 | 0.84 | ALDH1A1 (0.52) | HSD11B1PKLRTACR1KMT2AMEN1 | |
| SCHEMBL3527130 | 0.82 | HSD11B1 (0.42) | HSD11B1OPRM1TACR1KMT2ATET3 | |
| SCHEMBL28123227 | 0.82 | TACR1 (0.44) | HSD11B1TACR1KMT2AMEN1EPHX2 | |
| SCHEMBL20004190 | 0.82 | HSD11B1 (0.60) | HSD11B1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7317007-B2 | Benzothiazole derivatives with activity as adenosine receptor ligands | HOFFMANN-LA ROCHE INC. (US) | 2008-01-08 | — | — | US | claimed |
| US-20060003986-A1 | Benzothiazole derivatives with activity as adenosine receptor ligands | ALANINE ALEXANDER | 2006-01-05 | — | — | US | claimed |
| US-8383821-B2 | NK-1 and serotonin transporter inhibitors | BRISTOL-MEYERS SQUIBB COMPANY (US) | 2013-02-26 | — | — | US | disclosed |
| US-8026257-B2 | Substituted heterocyclic ethers and their use in CNS disorders | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-09-27 | — | — | US | disclosed |
| US-20100087434-A1 | NK-1 and Serotonin Transporter Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2010-04-08 | — | — | US | disclosed |
| US-20100075959-A1 | BENZOTHIAZOLE DERIVATIVES WITH ACTIVITY AS ADENOSINE RECEPTOR LIGANDS | ALANINE ALEXANDER | 2010-03-25 | — | — | US | disclosed |
| US-20090018132-A1 | Substituted Heterocyclic Ethers and Their Use in CNS Disorders | BRISTOL-MYERS SQUIBB COMPANY | 2009-01-15 | — | — | US | disclosed |
| WO-2009009411-A1 | SUBSTITUTED HETEROCYCLIC ETHERS AND THEIR USE IN CNS DISORDERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-01-15 | — | — | WO | disclosed |
| US-20080125419-A1 | BENZOTHIAZOLE DERIVATIVES WITH ACTIVITY AS ADENOSINE RECEPTOR LIGANDS | ALANINE ALEXANDER | 2008-05-29 | — | — | US | disclosed |
| US-20080108809-A1 | BENZOTHIAZOLE DERIVATIVES WITH ACTIVITY AS ADENOSINE RECEPTOR LIGANDS | ALANINE ALEXANDER | 2008-05-08 | — | — | US | disclosed |
| US-7317007-B2 | Benzothiazole derivatives with activity as adenosine receptor ligands | HOFFMANN-LA ROCHE INC. (US) | 2008-01-08 | — | — | US | disclosed |
| US-20050026906-A1 | Benzothiazole derivatives with actitvity as adenosine receptor ligands | ALANINE ALEXANDER (FR) | 2005-02-03 | — | — | US | disclosed |
| US-6835732-B2 | Modulation of the adenosine A2A receptor; cardioprotective agents; antiischemic agents; antihypoxia agents; central nervous system disorders, Alzheimer's disease, Parkinson's disease, anxiolytic agents; antidepressants; analgesics | HOFFMAN-LA ROCHE INC. | 2004-12-28 | — | — | US | disclosed |
| US-20030176695-A1 | Benzothiazole derivatives with activity as adenosine receptor ligands | ALANINE ALEXANDER (FR) | 2003-09-18 | — | — | US | disclosed |
| CN-1437471-A | Benzothiazole derivatives | HOFFMANN LA ROCHE (CH) | 2003-08-20 | — | — | CN | disclosed |
| US-20030125318-A1 | Benzothiazole derivatives with activity as adenosine receptor ligands | ALANINE ALEXANDER (FR) | 2003-07-03 | — | — | US | disclosed |
| EP-1303272-A2 | BENZOTHIAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-04-23 | — | — | EP | disclosed |
| US-6521754-B2 | Such as N-4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-2-methyl-isoni cotinamide | HOFFMAN-LA ROCHE INC. | 2003-02-18 | — | — | US | disclosed |
| US-20020045615-A1 | Benzothiazole derivatives with activity as adenosine receptor ligands | F.HOFFMANN-LA ROCHE AG (CH) | 2002-04-18 | — | — | US | disclosed |
| WO-2001097786-A2 | BENZOTHIAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2001-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060003986-A1 | Benzothiazole derivatives with activity as adenosine receptor ligands | ADORA2A, ADORA1, ADORA3 | HSD11B1 4050/4885OPRM1 1103/4885CCR1 4040/4885 |
| US-20080108809-A1 | BENZOTHIAZOLE DERIVATIVES WITH ACTIVITY AS ADENOSINE RECEPTOR LIGANDS | ADORA2A, ADORA1, ADORA3 | HSD11B1 4050/4885OPRM1 1103/4885CCR1 4040/4885 |
| US-20080125419-A1 | BENZOTHIAZOLE DERIVATIVES WITH ACTIVITY AS ADENOSINE RECEPTOR LIGANDS | ADORA2A, ADORA1, ADORA3 | HSD11B1 4127/4885OPRM1 1186/4885CCR1 4090/4885 |
| US-20030125318-A1 | Benzothiazole derivatives with activity as adenosine receptor ligands | ADORA2A, ADORA1, ADORA3 | HSD11B1 4050/4885OPRM1 1103/4885CCR1 4040/4885 |
| US-20030176695-A1 | Benzothiazole derivatives with activity as adenosine receptor ligands | ADORA2A, ADORA1, ADORA3 | HSD11B1 4050/4885OPRM1 1103/4885CCR1 4040/4885 |
| US-20050026906-A1 | Benzothiazole derivatives with actitvity as adenosine receptor ligands | ADORA2A, ADORA1, ADORA3 | HSD11B1 4492/4885OPRM1 1135/4885CCR1 3524/4885 |
| US-20100075959-A1 | BENZOTHIAZOLE DERIVATIVES WITH ACTIVITY AS ADENOSINE RECEPTOR LIGANDS | ADORA2A, ADORA1, ADORA3 | HSD11B1 4127/4885OPRM1 1186/4885CCR1 4090/4885 |
| US-20100087434-A1 | NK-1 and Serotonin Transporter Inhibitors | SLC6A4, TPH1, SLC6A2 | HSD11B1 570/4885OPRM1 264/4885CCR1 452/4885 |
| US-20020045615-A1 | Benzothiazole derivatives with activity as adenosine receptor ligands | ADORA2A, ADORA1, ADORA3 | HSD11B1 4050/4885OPRM1 1103/4885CCR1 4040/4885 |
| US-20090018132-A1 | Substituted Heterocyclic Ethers and Their Use in CNS Disorders | CNR1, CNR2, PMP22 | HSD11B1 398/4885OPRM1 209/4885CCR1 736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.